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Abstract
Background: Patients frequently fail to receive adequate pain relief from, or are intolerant of, first-line therapies
prescribed for neuropathic pain (NeP). This refractory chronic pain causes psychological distress and impacts
patient quality of life. Published literature for treatment in refractory patients is sparse and often published as
conference abstracts only. The aim of this study was to identify published data for three pharmacological
treatments: pregabalin, lidocaine plaster, and duloxetine, which are typically used at 2
nd line or later in UK patients
with neuropathic pain.
Methods: A systematic review of the literature databases MEDLINE, EMBASE and CCTR was carried out and
supplemented with extensive conference and grey literature searching. Studies of any design (except single patient
case studies) that enrolled adult patients with refractory NeP were included in the review and qualitatively
assessed.
Results: Seventeen studies were included in the review: nine of pregabalin, seven of the lidocaine plaster, and one
of duloxetine. No head-to-head studies of these treatments were identified. Only six studies included treatments
within UK licensed indications and dose ranges. Reported efficacy outcomes were not consistent between studies.
Pain scores were most commonly assessed in studies including pregabalin; trials of pregabalin and the lidocaine
plaster reported the proportion of responders. Significant improvements in the total, sensory and affective scores of
the Short-form McGill Pain Questionnaire, and in function interference, sleep interference and pain associated
distress, were associated with pregabalin treatment; limited or no quality of life data were available for the other
two interventions. Limitations to the review are the small number of included studies, which are generally small, of
poor quality and heterogeneous in patient population and study design.
Conclusions: Little evidence is available relevant to the treatment of refractory neuropathic pain despite the
clinical need. There is a notable lack of high-quality comparative studies. It is evident that there is a need for
future, high quality trials, particularly “gold-standard” RCTs in this refractory patient population.
Background
Neuropathic pain (NeP) is defined as “pain initiated or
caused by a primary lesion or dysfunction in the nervous
system” [1]. Patients experience pain described most fre-
quently as burning, tingling or electric shock [2]. It is gen-
erally persistent and/or chronic in nature and can be
further categorised as either peripheral or central depend-
ing on the origin of the lesion or dysfunction [1,3,4]. The
type of pain experienced varies considerably between NeP
sub-types and within sub-types. Pain may be present with
or without a stimulus continually (though intensity may
vary) or intermittently [5].
NeP is a widespread condition, with an annual incidence
of almost 1% of the general population [6]. Triggers for
NeP include cancer, diabetes and HIV infection, as well as
surgery, radiation and inflammation [5]. Common NeP
syndromes include diabetic peripheral neuropathy (DPN),
trigeminal neuralgia (TN) and complex regional pain syn-
drome (CRPS). NeP is more common in women and inci-
dence increases with age [6]. The prevalence of NeP is
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any medium, provided the original work is properly cited.expected to rise due to population aging and the increased
longevity of patients with cancer, HIV-infection, diabetes
and other diseases [5].
Resistance, insensitivity or intolerability to first-line
treatments is common [7]. To the authors’ knowledge,
there are no published definitions of refractory NeP, but
there is a proposed definition of pharmacoresistant NeP:
“A neuropathic pain condition is resistant to pharma-
cotherapy when mono-or a rational combination treat-
ment using drugs proven efficacious in RCTs fails in
inducing useful pain relief from the patient’s/physician’s
point of view after an appropriate duration of treatment
with adequate dosage, or if intolerable side effects
occur” [8]. Owing to the lack of a consensus definition
of refractory NeP, this review took a pragmatic approach
to define refractory NeP more broadly as patients who
had failed to receive adequate pain relief from or were
intolerant to previous therapy irrespective of the dura-
tion, dose and type of previous therapy.
Persistent pain syndromes cause suffering and psycho-
logical distress in association with reductions in quality
of life [9]. Despite this clinical need, there are few pub-
lished studies on refractory pain, and these are fre-
quently reported as conference abstracts rather than in
full peer-reviewed publications, which may be difficult
for clinicians to locate. Recent reviews of treatment effi-
cacy in specific NeP conditions, have offered little focus
on the refractory patient setting [10-12]. The reviewers
predicted that the class of evidence would be low, but
aimed to identify and summarise this literature in one
review to ensure accessibility of this clinically valuable
data. The aims of this review were:
a) to identify the evidence base in refractory neuro-
pathic pain for three pharmacological treatments (prega-
balin, lidocaine plaster and duloxetine) which are
typically used at 2
nd line or later in UK patients with
neuropathic pain, and
b) to determine the efficacy, safety and tolerability of
these drugs in this refractory patient population.
Methods
Literature searches
A comprehensive search of the major literature data-
bases Medline (In-process and other non-indexed cita-
tions), Embase and the Cochrane Clinical Trial Registry
was undertaken. The databases were searched from 1st
January 1998 to 12th December 2008. The comprehen-
sive search strategy, which was aimed to retrieve all stu-
dies in neuropathic pain and was not restricted by
refractory terms, can be found as an additional material
to this publication (additional file 1). In addition,
abstracts from eleven conferences (World Congress of
Pain, NeP Specialist Interest Group (NeuPSIG), British
Pain Society, European Congress on Neuropsychophar-
macology, American Academy of Neurology, European
Federation of Neurological Societies, European Neurolo-
gical Society, American Society of Anaesthesiologists,
European Society of Anaesthesiologists, World Congress
of Anaesthesiologists, Congress of the International
Anaesthesia Society) were hand-searched between 2004-
2008. The OpenSIGLE (System for Information on Grey
Literature) and Google Scholar databases were also
searched using multiple keyword searches to identify
additional studies published in the disease area; approxi-
mately 3500 and 5500 references were reviewed in the
Open SIGLE and Google scholar databases respectively.
Inclusion/Exclusion criteria
Studies that enrolled adult patients with refractory NeP
(central or peripheral) due to any cause, or lower back
pain with a neuropathic component were included
(Table 1). It was predicted that the evidence base for
the review would be limited. Therefore, studies of any
design, quality or sample size (except case studies for
one patient) were included. Owing to the lack of a con-
sensus definition of refractory NeP, this review took a
pragmatic approach to define refractory NeP broadly as
patients who had failed to receive adequate pain relief
from or were intolerant to previous therapy irrespective
of the duration, dose and type of previous therapy. Due
to the limited number of studies available, all studies
assessing ‘refractory’ patients using alternative defini-
tions or where undefined were also included in this
review. Studies enrolling a mixed population of refrac-
tory and non-refractory patients were included. All stu-
dies of refractory patients were included irrespective of
number or type of previous treatments or duration of
previous treatment. Included interventions were prega-
balin, the lidocaine plaster and duloxetine, as monother-
apy or in combination. Only publications in English
were included. These criteria were applied to both cita-
tions retrieved from databases and hand-searching.
Study procedures
A rigorous systematic review process was conducted in
accordance with the QUORUM guidelines [13]. A team
of reviewers independently determined the eligibility of
each publication by applying the inclusion/exclusion cri-
teria. Each publication was reviewed by two reviewers,
and any discrepancies in the decision for inclusion
between these reviewers were resolved by a third
reviewer. As several studies reported data in more than
one publication, all publications of a single study were
c o m p i l e di n t oas i n g l ee n t r yi nt h ed a t ae x t r a c t i o ng r i d
to avoid double counting of patient data. All efficacy,
safety and tolerability data from eligible publications
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base. All data were double-extracted in parallel by two
reviewers and any discrepancies were resolved by a third
reviewer.
Critical appraisal
A qualitative critical appraisal was carried out to assess
the methodological quality and appropriateness of study
design of each included study. A bespoke, qualitative
critical appraisal tool was developed specifically for use
in this review based on a number of published critical
appraisal tools [14-17]. The development of a new criti-
cal appraisal tool was deemed necessary after assessing
current instruments. The Jadad scale [18] which is often
used in quality appraisal of randomised controlled trials
(RCTs) was unsuitable for this review as the majority of
included studies are not RCTs. A checklist for the
assessment of the methodological quality both of rando-
mised and non-randomised studies of health care inter-
ventions developed by Downs and Black was found to
be more appropriate [19]. However, this tool consists of
a detailed questionnaire, which was inappropriate for
the brief content of several of the included studies only
available as conference abstracts. Hence a new scale was
developed which qualitatively covers the key topics cov-
ered in the Downs questionnaire (reporting, bias and
confounding effects, usefulness to the study question-see
Table 2).
Analysis
No meta-analysis or quantitative analysis was possible
due to significant heterogeneity between included studies
in terms of study design and size, and patient population
(types of NeP included). Further, the inconsistencies in
outcomes reported and the paucity of statistical data pre-
vented quantitative meta-analysis. The review therefore
consists of a qualitative assessment and narrative analysis
to compare the studies.
Results
Trial Flow
Of the 4789 references retrieved from the literature
databases, and 244 reference sr e t r i e v e df r o mt h eh a n d
searching, 21 publications met the inclusion criteria
(Figure 1). Following linking of multiple publications per
study, 17 studies were included. Reasons for study
exclusion are presented in Figure 1.
Trial Characteristics
The characteristics of the 17 studies included in the
review are presented in Table 3. Seven of the studies
were published solely as conference abstracts, while the
Table 1 Study inclusion and exclusion criteria
Criteria Included Excluded
Type of study All study designs, both prospective and retrospective (except case studies for one patient) Case studies for one patient
Population Adult patients
NeP due to any cause (central or peripheral)
Treatment-refractory NeP (as defined in the included studies)
Studies in children
Treatment naive patients
Study size Any None
Trial length Any None
Interventions Pregabalin
Lidocaine plaster
Duloxetine
Other treatment for NeP
Comparator Any/None -
Language English language only Non-English language
Table 2 Critical appraisal
Reporting Did the study address a clearly defined issue?
Did the authors use an appropriate method to answer the review question?
Are the main outcomes, patient population and interventions tested clearly described?
Are losses to follow-up reported and clearly described?
Bias and confounding effects Were the patients recruited in an acceptable way?
Was any attempt to randomise or blind patents or investigators reported?
Have the authors identified all/any of the confounding factors?
Was the follow-up of patients complete and long enough?
Usefulness of the study Are the results useful to answer the review question?
Do the results fit with the evidence from other studies?
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tions at the time of searching in December 2008.
Nine studies were identified in refractory NeP patients
for pregabalin, seven for the lidocaine plaster and one
study was available for duloxetine (Figure 2). Six studies,
all assessing pregabalin were within the UK license, as
reported by the European Medicines Agency (EMA) for
pregabalin and duloxetine and the MHRA UK license
for the lidocaine plaster, which was licensed by country
rather than centrally by the EMA.
The types of NeP examined in the included studies
were diverse (Table 3 and Table 4). Pregabalin was
trialled in a variety of refractory conditions including
DPN, postherpetic neuralgia (PHN), TN and CRPS. The
lidocaine plaster was trialled additionally in lower back
pain with a neuropathic component, but not in TN. Of
the two lidocaine plaster trials including patients with
lower back pain, one trial enrolled patients with non-
radicular lower back pain (LBP), who reported moder-
ate-to-severe pain on the neuropathic pain scale at
study enrolment [20]. The other enrolled only four
patients of which two patients had back pain with a
neuropathic component; in one patient the presence of
this component was unclear and the final patient had
CRPS [21]. Duloxetine was only studied in TN.
Although a number of different types of studies were
identified, including audits, case series and active con-
trolled trials, the majority of included studies were sin-
gle arm trials (Table 3). No head-to-head studies
comparing the included treatments of pregabalin, dulox-
etine and the lidocaine plaster were found. Only one
RCT (for the lidocaine plaster) was identified, which was
crossover in design [22]. One active controlled trial
compared two doses of duloxetine [23], while the other
compared pregabalin to gabapentin [24]. Study duration
varied across the included studies.
Few studies reported detailed definitions of ‘refractory’
NeP and in some cases, no definition was provided
(Table 3). Previous failed medications were not always
reported, nor were concomitant medications taken by
trial participants. Where reported, commonly permitted
concomitant medications included anticonvulsants and
mood stabilisers such as carbazapine, tricyclic antide-
pressants (TCAs) and gabapentin (Table 5). Eight of the
nine pregabalin studies trialled the intervention in
patients who were refractory to gabapentin.
Trial Quality
Approximately half of the studies did not define or
clearly report the study question. Withdrawals, an
important aspect to determine complete follow-up of
patients, were reported in the majority of pregabalin
trials (7/9) but less frequently in the lidocaine plaster
studies (4/7). The duloxetine study did not report with-
drawals [23]. Bias and confounding factors were not
addressed in many of the studies, most likely due to the
brevity of information presented in the abstracts. Almost
all of the included studies were single arm trials, which
prevented direct and indirect comparisons of the inter-
ventions of interest.
Comparison of efficacy outcomes
Mean pain scores were widely reported in the included
trials, particularly for pregabalin (7 studies) (Table 6). In
comparison, these outcomes were reported infrequently
in trials of the lidocaine plaster and duloxetine (three
and one studies respectively). All studies for pregabalin
reported that the reduction in pain intensity was statisti-
cally significantly reduced following treatment; only one
of the three studies reported statistical significance for
this outcome in the lidocaine plaster studies. The dulox-
etine study reported that pain severity (measured by
visual analogue scale (VAS)) was statistically significantly
reduced at endpoint compared to baseline.
The proportion of responders was well reported for
both pregabalin and the lidocaine plaster (Table 6); but
there is considerable variation between trials, which may
be explained by the variety of study designs identified.
The duloxetine study did not report this outcome. The
percentage of patients achieving complete pain relief
was similar for both pregabalin and lidocaine plaster
(25% and 13%-22% respectively). In comparison the per-
centage of patients achieving pain reduction of at least
50% varied greatly; most likely due to the diversity of
trial designs. A similar trend was observed for the
percentage of patients achieving a pain reduction of
Figure 1 Trial flow. * Includes conference searching, Google
scholar and Open SIGLE. Approximately 3500 references were
reviewed in Open SIGLE and approximately 5500 references were
reviewed in Google scholar.
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Study
reference
Study
location
Type of
trial*
Study
duration
No.
pts
Treatment and
dose
Study population % pts
refractory
Reporting and
definition of refractory
Pregabalin
Freynhagen
2007 [27]
Germany Single-arm
trial
4 weeks 55 Pregabalin
titrated from
75-600 mg/day
Polyneuropathy, chronic
radiculopathy***,
encephalitis disseminate,
PHN, neuropathic cancer
pain, acute herpes zoster
infection, CRPS (CRPS II),
other
100% Diagnosis stated by the
referring physician as
“refractory NeP”,
“intractable NeP”,
“problematic NeP” or
similar wording.
Definition not reported.
Obermann 2008
[33]
Germany Single-arm
trial
52 weeks 53 Pregabalin
titrated from 50-
75 mg/d
Mean (SD) dose
245 (77) mg/d at
day 14
TN with and without
concomitant facial pain.
94% All but three of patients
had received prior therapy,
therefore may be
considered refractory.
Sommer 2007
[34]
Germany Single-arm
trial
Unclear
(mean
duration of
continuous
pregabalin
intake 217
days)
19 Pregabalin 75 mg
bid was titrated.
Mean effective
dose (SD); 305
(185) mg
Restless Leg Syndrome
with; Polyneuropathy,
small fibre neuropathy,
neurinomata.
89% All but two patients had
received prior therapy,
therefore may be
considered refractory.
Reasons for
discontinuation of therapy
were lack or loss of
efficacy, side effects and/
or augmentation.
Ambesh 2008
[24] (A)
Unclear Unclear,
active
controlled
Follow-up
was 2-18
months
86 Gabapentin 300
mg tid
Gabapentin 150
mg and
Pregabalin 75
mg bid
Pregabalin 150
mg bid
NeP. 100% Patients are “resistant to
current analgesic
treatment regimens or
conventional pain
therapies”.
Patients with “intractable
NeP”.
Definition not reported.
Allen 2005 [26]
(A)
UK Single-
arm trial
Up to 6
months
18 Mean dose of
pregabalin was
600 mg/day
NeP. 100% Patients with NeP
“inadequately controlled
by gabapentin”.
Definition of refractory
not reported.
Douglas 2008
[41] (A) [linked
to Douglas
2006 [31]]
UK Audit Data
reported
for 3
months
30 Pregabalin
dosing
“according to
BNF
recommended
standard regime”
NeP. 100% Patients who “failed to
respond to or who had
been unable to tolerate
first and second-line
neuropathic pain agents”.
Hanu-Cernat
2005 [32] (A)
UK Audit Not stated 47 Dosing not
stated
Variety of NeP conditions. 100% Patients with an
“unsatisfactory response
to drugs”.
Patients who were
previously treated with
gabapentin which “failed
to relieve the symptoms”
or where the “dose could
not be escalated due to
side-effects”.
Stacey 2008
[29] [linked to
D’Urso De Cruz
2005; D’Urso
De Cruz 2005;
Siffert 2005
[42-44]]
United
States
Single-
arm trial
65 weeks 81 Pregabalin 150
mg/day titrated
up to a max of
600 mg/d
DPN, PHN** 100% Patients refractory to at
least 6 months of usual
care for NeP.
Definition of refractory;
discontinuation of a
medication due to the
inadequate effectiveness
after 2 weeks of
treatment at the
minimum recommended
doses, intolerable adverse
events, or both.
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Toth 2007 [30]
(A)
Unclear Single-
arm trial
Unclear
(Av.
treatment
duration
26 weeks)
33 Average dose
375 mg of
pregabalin
NeP due to PN. 30% (only data
on refractory
patients-i.e.
non-
responders to
gabapentin
was extracted)
Responders and non-
responders to
gabapentin.
Definition of non-
responders not reported.
Lidocaine plaster
Galer 1999 [22] United
States
RCT,
placebo
controlled
Enriched
enrolment
design
4 weeks (28
days max.)
32 Lidocaine 5%
plaster (700 mg/
plaster) applied as
3 plasters per day
to the PHN region
Placebo plaster, 3-
5 plasters/day (10
× 14 cm)
PHN Unclear Compassionate use
protocol enrolling patients
who were participants of
a previous study of the
lidocaine plaster who had
requested open-label use
and those who were
“refractory PHN patients”.
Definition of refractory not
reported.
Hines 2002 [21] United
States
Case series Not stated 4 Lidocaine plaster
5% (Lidoderm)
Low back pain (2 patients
with neuropathic
component, 1 patient
unclear if neuropathic
component; lumbar
degenerative disc disease,
L4-L5 arthrodesis, and
complex regional pain
syndrome type 2 in 1
patient)
100% All patients had previous
treatment. The definition
of refractory varied across
patients from inadequate
control of symptoms to
intolerant of treatment.
Devers 2000
[28]
United
States
Single-arm
trial
Mean
duration
6.2 weeks
16 Up to 3 plasters
directly to the
painful area
Wear plasters up
to a max 12
hours/day
NeP due to:
Postthoractomy, Stump
neuroma, Intercostal
neuralgia, Abdominal
neuroma
Radiculopathy***,
Meralgia paresthetica,
CRPS type 1, Diabetic
polyneuropathy,
Postmastectomy
100% All patients had been
enrolled in prior drug
trials, of which were
unsuccessful; “either
resulted in intolerable side
effects of inadequate
partial pain relief”.
Robert 2005
[25](A)
Unclear Case series Not stated 3 Lidocaine plaster
5%
Central NeP syndromes
due to: Spinal injury, IV
infusion of infliximab
100% All patient had been
treated with previous
therapy, however all
“patients continued to
experience excruciating
pain”.
Argyra 2005
[35](A)
Unclear Single-arm
trial
Unclear
(length of
treatment 2
months-4
years,
mean 18
months)
36 Lidocaine 5%
plaster
Two plasters used
every 24 hours
PHN, Posthoracotomy
syndrome, Post
mastectomy pain, DPN,
CRPS, Peripheral ischaemia
due to autoimmune
disease
100% Patients “resistant to
therapy”.
Galer 2004 [20] United
States
Single-arm
trial
6 weeks 71 Lidocaine plaster
5% daily, max. 4
plasters
Low-back pain (enrolled
patients with non-
radicular LBP, who
reported moderate-to-
severe pain on the
neuropathic pain scale at
study enrolment)
100% Patients with the
“moderate to severe pain
... at baseline despite prn
or stable doses” of
previous treatment.
Galer 2003 [36] Unclear Survey Not
reported
(mean
length of
plaster use
7.6 years)
20 Lidocaine 5%
plaster; the mean
number of
plasters applied
to the PHN region
was 2.3/d (range
1-5/day)
PHN 100% The conclusion states that
this study assessed “long
term
pharmacotherapeutic for
a refractory neuropathic
pain condition”. Subjects
were offered
“compassionate use of the
lidocaine plaster”.
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not respond to treatment ranged from 6% to 46%.
Comparison of quality of life outcomes
A substantial quality of life data-set was available for preg-
abalin; four of the nine included studies reported data for
these outcomes (Table 6). Other than one study reporting
a significant improvement in quality of sleep, no quality of
life outcomes were reported in studies of the lidocaine
plaster [25] and no results were available for duloxetine. In
comparison significant improvements for pregabalin were
observed in several aspects of q u a l i t yo fl i f ei n c l u d i n g ;
overall quality of life (SF-MPQ total, sensory and affective
scores (Figure 3) and SF-12), function interference, sleep
interference, interference of mood, daily activities and pain
associated distress Figure 4). One study assessing pregaba-
lin also reported that significant improvements in patients’
global impression of change (PGIC) were demonstrated
[26].
Treatment satisfaction was reported for one trial of
pregabalin and two trials for the lidocaine plaster. A
case series study of four patients using the lidocaine
plaster described one patient as “satisfied with his pain
control”. A second study of 20 patients, reported that
the mean satisfaction with pain relief from the lidocaine
plaster was 3.8 on a scale ranging from-5 (extremely dis-
satisfied) to +5 (extremely satisfied). One pregabalin
study reported that over 60% of patients were satisfied
with treatment, while 65% of physicians were satisfied
with treatment [27].
Efficacy in patient subgroups
Pregabalin has been demonstrated to be efficacious
across a broad range of NeP conditions. Devers et al.
Reported 13 out of 16 patients with a wide range of
NeP conditions achieved at least moderate pain relief
with the lidocaine plaster [28]. One study reported a
subgroup analysis for DPN and PHN patients and
observed that pregabalin effectively reduced pain inten-
sity in both subgroups with similar magnitude [29].
Pregabalin showed efficacy benefits in patients with
NeP inadequately controlled by gabapentin as 8 of the 9
pregabalin studies included patients, who had previously
failed on gabapentin (Table 5). A number of these stu-
d i e sr e p o r t e dap o s i t i v er e s p o n s et op r e g a b a l i ni n
patients previously treated with adequate doses of gaba-
pentin [26,27,29-32].
Safety
Adverse events (AEs) were poorly reported with only
eight studies reporting data for the proportion of
patients who experienced any AE; three studies for preg-
abalin, four for the lidocaine plaster and one for duloxe-
tine (Table 7). The proportion of patients who
experienced AEs varied greatly between the trials for
each intervention, in total ranging from zero to 42%.
The most commonly reported AEs associated with
pregabalin treatment were dizziness (range 16-66%) and
somnolence (range 15-40%) [27,29,33,34]. Application
site reactions/papules (4-28%) and local erythema (14-
15%) were commonly reported with lidocaine plaster
administration [20,22,28,35,36]. No safety data for
duloxetine regarding specific AEs were reported.
Tolerability
Withdrawals were reported for pregabalin (six studies)
and the lidocaine plaster (four studies). No data was
available for duloxetine. The proportion of patients
withdrawing from studies varied considerably. Total
Table 3: Summary of included trials (Continued)
Duloxetine
Restivo 2008
[23]
Greece Unclear,
active
controlled
12 weeks 18 Duloxetine 60
mg/day
Duloxetine 120
mg/day
TN 100% Patient were “refractory to
medical treatment”.
Definition not reported
*All trials are single arm, unless otherwise stated. The type of trial was as reported by the authors. (A) indicates that only a conference abstract was available. NR;
Not reported. All studies were prospective in design, with the exception of two [21,32]. Studies which do not use the licensed dose of the intervention and/or do
not study the use of the intervention in a licensed indication are italicised (UK license, as reported by the European Medicines Agency (EMA) for pregabalin and
duloxetine and the MHRA UK license for the lidocaine plaster, which was licensed by country rather than centrally by the EMA). **Fibromyalgia patients were
also enrolled in this study, however data for these patients were reported separately and were not extracted for this review. ***Patients with radiculopathy are
assumed to have radiculopathy with a neuropathic component as the studies state that patients with neuropathic conditions are included.
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pregabalin. For the lidocaine plaster the range was nar-
rower from 6% up to 11%. Withdrawals due to AEs ran-
ged from 5.5% to 14.3% for pregabalin and 2.8% to 8.5%
for the lidocaine plaster.
AEs were the main reason for withdrawals for both
treatments. AEs leading to withdrawals were linked clo-
sely to commonly reported AEs for each treatment. For
example, common AEs leading to pregabalin withdrawal
included dizziness, drowsiness and weight gain, while
AEs leading to withdrawal from lidocaine plaster use
included rash and skin redness. Approximately 5% of
patients withdrew due to lack of efficacy for both
treatments.
Study Limitations
The findings of this review are from a systematic and
comprehensive search of the literature, aiming to collate
all evidence on the treatments in question in refractory
NeP in an unbiased and thorough manner. We do how-
ever note that there are limitations to this review. These
include the finding that there are only a small number
Table 4 Summary of previous, concomitant and add-on therapy
Study reference Previous medication Concomitant/add-on medication
Pregabalin
Freynhagen 2007 [27] Anticonvulsants (except pregabalin), Antidepressants
Cannabinoids, Gabapentin, Muscle relaxants, NSAID/COX-2
inhibitor, Opioids
Analgesics, Non-pharmacological treatment
Obermann 2008 [33] Carbamazepine, Gabapentin, Oxcarbazepine Carbamazepine, Lamotrigine
Sommer 2007 [34] Cabergoline, Gabapentin, L-DOPA, Pergolide,
Pramipexole, Roprinole, Roprinole + tilidine, Tilidine
Pramipexole + tilidine/naloxone
Pramipexole + fentanyl patch
Ambesh 2008 [24] (A) Current analgesic treatment regimens, Conventional
pain therapies
Amitriptyline
Allen 2005 [26] (A) Gabapentin NR
Douglas 2008 [41] (A) [linked to
Douglas 2006 [31]]
Tricyclics, Gabapentin NR
Hanu-Cernat 2005 [32] (A) Gabapentin, Pregabalin NR
Stacey 2008 [29] [linked to D’Urso
De Cruz 2005; D’Urso De Cruz
2005; Siffert 2005 [42-44]]
Anticonvulsants, Gabapentin, NSAIDs/Cox IIs, Opoid
analgesics, Pregabalin, SSRI, SNRI, Tramadol, Tricyclics
Tricyclics, Gabapentin
Toth 2007 [30] (A) Gabapentin NR
Lidocaine plaster
Galer 1999 [22] Unclear; enriched enrolment design-patients either were
treated with the lidocaine plaster and requested open-
label use, or were refractory to previous treatment,
although type of previous treatment was unclear.
Acetaminophen, Opiates, NSAIDs, Tricyclics
Hines 2002 [21] Hydrocodone/acetaminophen, NSAIDs, Sertraline,
Diazepam, Rofecoxib, Oxycodone, Progesterone therapy,
Gabapentin, Atenolol, Ibuprofen, Opioid analgesics,
Clonidine, Citalopram, Olanzapine, Lorazepam,
Cyclobenzaprine, Hormone replacement therapy,
Hydrocodone, Fluoxetine, Amitriptyline, Venlafaxine,
Buspirone
Tramadol, Sustained-release diltiazem, Hormone
replacement therapy, Triamterene, Amitriptyline,
Sertraline, Diazepam, Rofecoxib
Oxycodone controlled-release tablets, Tizanidine,
Progesterone therapy, Verapamil, Clonidine, Baclofen
Venlafaxine, Gabapentin
Devers 2000 [28] Anticonvulsants, Eutectic mixture of local anaesthetics,
Lidocaine, Mexiletine, Opoids, Prilocaine (EMLA) cream,
Tricyclics
Amitriptyline, Acetamenophen, Carbamazepine, Fentanyl
patch, Gabapentin, Hydromorphone, Lamotrigine,
Methadone, Nortriptyline, Oxycodone, Paroxetine.
Robert 2005 [25](A) Combinations of conventional anti-neuropathic drugs:
Anticonvulsants, Free radical scavengers, Ketamine,
Opioids, Tricyclics.
NR
Argyra 2005 [35](A) NR Lidocaine was tested as an add-on therapy, although
other treatments were not reported.
Galer 2004 [20] Cyclo-oxygenase-2 (COX-2) inhibitors, Non-selective
NSAIDs, Gabapentin, Tramadol, Opioids
NR
Galer 2003 [36] Topical lidocaine plaster Anticonvulsants, Acetaminophen, Conticosteroids,
Opioids, Tricyclics.
Duloxetine
Restivo 2008 [23] NR NR
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Page 8 of 13of included studies identified, all of which are heteroge-
neous in terms of patient population and study design.
The studies are generally small, of poor quality, and
enrol a large number of different refractory NeP condi-
tions. This therefore limits meaningful comparisons
between treatments in order to determine relative
effectiveness.
Discussion
Since a considerable number of patients suffer persistent
or refractory NeP, one might expect a larger evidence
base to be available [4]. The findings of this comprehen-
sive systematic review indicate little clinical evidence is
available for the refractory treatment setting. Only
seventeen studies met the inclusion criteria of which
seven were available as conference abstracts only. When
considering the three included treatments in this review
t h ee v i d e n c eb a s ef o rp r e g a b a l i ni nt h er e f r a c t o r yN e P
population is stronger than for the lidocaine plaster or
duloxetine. This is particularly apparent when consider-
ing only studies within UK licensing.
The studies included in this review were heterogenous
in their design and reported outcomes. Patient populations
enrolled were highly variable, ranging from a specific con-
dition such as TN or chronic lower back pain with a
neuropathic component to a “wide variety of NeP condi-
tions”. Pregabalin and the lidocaine plaster were trialled in
a wide variety of NeP conditions. The duloxetine study
enrolled a specific TN patient group, limiting generalisa-
bility to a clinical practice setting [23]. Both within and
between study differences in NeP types of included
patients are important factors, which should be considered
when drawing conclusions from the results of the review.
Study durations varied considerably with long-term data
on key efficacy outcomes available for pregabalin only.
Despite the lack of consistency in instruments used,
efficacy data is widely available for both pregabalin and
the lidocaine plaster. In contrast, only a concluding
statement (available as a conference abstract only) pro-
vided efficacy data for duloxetine. Relative differences
between the interventions cannot be determined owing
to the lack of head-to-head trials, or indeed any com-
parator controls to permit indirect comparisons. The
significance of reductions in pain score were reported
widely for pregabalin (significant in 7 out of 7 studies),
w h i l eo n l yo n eo ft h et h r e es t u d i e sf o rt h el i d o c a i n e
plaster using this outcome measure reported significant
reductions. Wide variation between trials hinders com-
parison of the proportion of responders between treat-
ments. Although treatment efficacy was reported in
Table 5 NeP sub-types studied in the included trials
Treatment Licensed indication Types of NeP studied within license Types of NeP studied outside of license
Pregabalin Peripheral and central
NeP
￿ NeP (variety)
￿ Polyneuropathy
￿ Chronic radiculopathy with a neuropathic
component
￿ PHN
￿ Diabetic peripheral NeP
￿ Neuropathic cancer pain
￿ CRPS (CRPS II)
￿ TN
￿ Restless Leg Syndrome with NeP
Lidocaine
plaster
PHN ￿ PHN ￿ Lower back pain with a neuropathic
component
￿ CRPS
￿ NeP due to
￿ Postthoractomy
￿ Stump neuroma
￿ Intercostal neuralgia
￿ Abdominal neuroma
￿ Radiculopathy
￿ Meralgia paresthetica
￿ Diabetic polyneuropathy
￿ Postmastectomy
￿ Peripheral ischemia
Duloxetine DPN - ￿ TN
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Page 9 of 13Table 6 Efficacy outcome reporting for each included intervention
Intervention
Pregabalin Lidocaine plaster Duloxetine
Mean Pain Scores-No. studies (no. patients receiving the intervention)
+ reporting reduction in mean pain scores compared to baseline
No. studies reporting data for any pain intensity outcome 7 3 1
McGill questionnaire 2* (109)
Pain reduction measured by VRS 2* (81)
Pain intensity measured by NRS 1* (30) 1NR (32)
Pain intensity measured by BPI 2* (73)
Pain score measured by NPS-10, NPS-8 and NPS-4 1* (71)
Pain intensity measured by present pain intensity (PPI) 1* (81)
Percentage pain score reduction 1NR (16)
Pain severity measured by VAS 1* (18)
Quality of life-No. studies (no. patients receiving the intervention)
+ reporting improvements in quality of life compared to baseline
No. studies reporting data for any quality of life outcome 4 1 0
SF-MPQ total, sensory and affective score 1*
Quality of life measured by the SF-12 1* (55)
Sleep interference measured by NRS 1* (55), 1NS (30)
Quality of sleep measured by VRS 1* (28)
Quality of sleep (instrument not reported) 1* (3)
Inference of mood measured by VRS 1* (28)
Daily activity measured by VRS 1* (28)
Function interference measured by NRS 1* (30)
Psychological stress measured by the Short Questionnaire on Current Burden 1* (55)
Pain associated distress measured by NRS 1* (30)
PGIC 1* (18)
Responders-No. studies (no. patients receiving the intervention)
+ reporting data for outcome
No. studies reporting data for any pain relief outcome 4 4 0
Complete pain relief 1 (53) 2 (48)
range of percentages reported 25% 13-22%
A lot of pain relief 2 (48)
range of percentages reported 25-34%
Moderate pain relief 2 (48)
range of percentages reported 33-44%
Pain reduction of ≥ 50% 3 (158) 2 (7)
range of percentages reported 33-49% 100%
a
Pain reduction 10-50% 2 (105) 1 (33)
range of percentages reported 17%
b NR
c
Non-responders 3 (132) 2 (52)
range of percentages reported 26-46% 6-20%
*Statistically significant; NS-not statistically significant; NR-statistical significance not reported.
+Numbers of patients receiving the intervention of interest.
aTwo case studies of 3 and 4 patients: the former reported all patients achieved 50% reduction in pain score, the latter reported improvements in all patients in
an inconsistent manner.
bOne study reported that 4 of 24 patients achieved pain relief of 10-25%. The second study reported 38 out of 78 evaluable patients experienced ≥ 30%
reduction in pain from baseline.
cOne study stated that patients experienced pain relief of 10%-50%, however it was unclear whether this referred to all patients.
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Page 10 of 13studies of a wide variety of NeP types, only one study
carried out subgroup analysis, demonstrating efficacy of
pregabalin in both DPN and PHN.
Quality of life data available for pregabalin indicated
significant improvements. Of note, observed quality of
life improvements in this patient population appears
consistent with improvements in a treatment naive
patient population [37].
Since completing this review, only one of the included
abstracts has been published as full text in a peer-reviewed
journal. The full report of the study by Toth [38] included
data for a greater number of patients compared to the ori-
ginal abstract, for both the gabapentin responder (32 ver-
sus 23 patients respectively) and non-responder groups
(29 versus 10 patients respectively) who were subsequently
treated with pregabalin. A non-responder to gabapentin
was defined as a patient who was unable to achieve at
least a 30% pain relief on the VAS). Patients were assessed
for both pain (using a VAS) and quality of life (using the
European Quality of Life-5 Domains (EQ-5D) instrument
and VAS), with only results from the pain relief presented
in the original abstract. Both gabapentin responder and
non-responder groups experienced similar pain relief as
reported in the original abstract (20-25%) following substi-
tution by pregabalin. There was also a statistically signifi-
cant improvement in the VAS measured and utility scale
quality of life in both responders and non-responders
compared to baseline (statistical significance for pain relief
was not reported in the original abstract). No serious
adverse events were reported for either medication. How-
ever, gabapentin non-responders discontinued pregabalin
in more than 30% of cases due to inefficacy or adverse
events. Data from the full publication further supports the
quality of life evidence base for pregabalin reported in this
systematic review.
Additionally, two studies have been published since
this review was conducted that would meet the inclu-
sion criteria [39,40]. Both studies examined the efficacy
of treatments in a refractory TN patient population. All
patients had been previously treated with carbamaze-
pine. The Rustagi et al. study was a randomised, cross-
over trial comparing the efficacy of pregabalin with
lamotrigine and was published as a conference abstract
[40]. The authors concluded that although the efficacy
of pregabalin was comparable to lamotrigine, pregabalin
was found to have better tolerability, which would
increase patient compliance when compared with lamo-
trigine. The study by Pérez et al. was a secondary analy-
sis of the LIDO study, which aimed to analyse the effect
of pregabalin on longitudinal health and non-health
resource utilisation [39]. This was a non-interventional,
12-week, prospective, multicentre observational study in
Spain that recruited patients with refractory NeP
(including DPN, PHN and TN). This study reported a
subgroup analysis on 65 patients identified with TN that
were refractory to previous analgesic therapy. Patients
received pregabalin as a monotherapy or as add-on ther-
apy; all patients were naive to pregabalin treatment. The
authors concluded that pregabalin was an effective
short-term treatment, showing improvements in PROs
such as pain reduction, anxiety, depression and sleep
disturbances. However the limitation of this study was
the lack of a relevant comparator.
Recommendations for future research
This review has highlighted the need for future, high
quality trials, particularly “gold-standard” RCTs in this
refractory patient population. Head-to-head trials would
enable further, direct (and indirect) comparisons
between treatments, as previously proposed [12].
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Figure 4 Quality of life outcomes measured by the NRS (sleep
and function interference, pain associated distress) for
pregabalin [22,41]. p values are compared to baseline. Freynhagen
2007, baseline N = 53, endpoint N = 50; Douglas 2008, baseline
N = 30, endpoint N = 30
Plested et al. BMC Neurology 2010, 10:116
http://www.biomedcentral.com/1471-2377/10/116
Page 11 of 13Currently, the main evidence for these treatments in
refractory NeP stems from single arm trials of lesser
quality.
In addition, a proposed consensus on the definition of
refractory NeP is required, since studies have been
shown to present a wide variety of meanings for the
term. Where definitions of refractory NeP were provided
in the included studies, these focused on either lack of
adequate pain relief of previous treatments (2 studies) or
a combination of intolerability/lack of pain relief to pre-
vious treatments (6 studies). No studies only referred to
intolerability when defining refractory NeP. Further, only
one study reported information regarding the dose and
duration of previous treatment, which is included in the
proposed definition of pharmacoresistant NeP [30]. Such
broad definitions can result in hugely diverse disease
severities both within and between studies, further limit-
ing the potential to compare between treatments. We
recommend further research both from the clinical com-
munity and from further real-world studies of this patient
population towards a consensus definition of refractory
NeP.
Conclusions
Little evidence is available relevant to the treatment of
refractory neuropathic pain despite the clinical need.
There is a notable lack of high-quality comparative
studies. Studies across all treatments included were
diverse, generally small and of poor quality. The cur-
rently available evidence base found all three treatments
to be efficacious in treating patients with refractory
NeP. However, it is evident that there is a need for
future, high quality trials, particularly “gold-standard”
RCTs in this refractory patient population. Further,
additional research may prove valuable in progressing
towards a consensus definition of refractory NeP.
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Table 7 Any AE
Study Name No. of
patients
No. with
any AE
Comments
Pregabalin
Obermann
2008
53 22
Sommer
2007
74
Hanu-Cernat
2005
24 Intolerable side effects occurred in five patients.
Lidocaine plaster
Hines 2002 4 0
Devers 2000 16 1
Galer 1999 32 No significant difference between lidocaine patch and placebo (p ≥0.492) for AEs that were reported by
at least 5% of the subjects in either treatment group.
Galer 2003 20 5
Duloxetine
Restivo 2008 18 3 For both treatment groups of duloxetine (60 mg/day and 120 mg/day).
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